The Korean journal of internal medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지
DOI QR코드

DOI QR Code

Serum vitamin D3 levels are not associated with thyroid cancer prevalence in euthyroid subjects without autoimmune thyroid disease

  • Choi, Yun Mi (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Won Gu (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Tae Yong (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Bae, Sung Jin (Health Promotion Center, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Hong-Kyu (Health Promotion Center, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jang, Eun Kyung (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Jeon, Min Ji (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Han, Ji Min (Department of Internal Medicine, Samsung Changwon Hospital, Sungkyunkwan University School of Medicine) ;
  • Shong, Young Kee (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine) ;
  • Kim, Won Bae (Department of Internal Medicine, Asan Medical Center, University of Ulsan College of Medicine)
  • Received : 2015.04.02
  • Accepted : 2015.09.13
  • Published : 2017.01.01
⟨ Previous Next ⟩

Abstract

Background/Aims: Previous studies have suggested that elevated serum vitamin D levels might protect against thyroid cancer. Elevated serum thyroid stimulating hormone levels and autoimmune thyroid disease (AITD) are suggested to be thyroid cancer promoting factors but have not been well controlled in previous studies. We designed the present study to evaluate whether serum vitamin D levels are associated with thyroid cancer in euthyroid patients with no clinical evidence of AITD. Methods: This cross-sectional study included subjects who underwent routine health check-ups, including serum 25-hydroxy vitamin D3 (25(OH)D3) levels, anti-thyroid peroxidase antibody (TPO-Ab), and thyroid ultrasonography (US). Inclusion criteria were euthyroid, negative TPO-Ab, and no evidence of AITD by US findings. Thyroid cancer diagnoses were based on fine needle aspiration cytology and/or postsurgical histopathological findings. Results: We enrolled 5,186 subjects (64% male, 37% female) in this study, including 53 patients (1%) with a diagnosis of thyroid cancer (33 males, 20 females). Mean 25(OH)D3 levels were similar between the thyroid cancer and control groups (p = 0.20). Subgroup analysis according to sex or seasonal variation also revealed no differences in 25(OH)D3 levels between the two groups. Based on the levels of 25(OH)D3, there was no significant difference in the prevalence of thyroid cancer; the prevalence was 0.71%, 0.94%, 1.40%, and 0.82% in the deficient, insufficient, sufficient, and excess groups, respectively (p = 0.64). Conclusions: The levels of serum 25(OH)D3 are not associated with thyroid cancer prevalence in euthyroid subjects with no clinical evidence of AITD.

Keywords

Acknowledgement

Supported by : Bumsuk Academic Research

References

  1. Rosen CJ, Adams JS, Bikle DD, et al. The nonskeletal effects of vitamin D: an Endocrine Society scientific statement. Endocr Rev 2012;33:456-492. https://doi.org/10.1210/er.2012-1000
  2. Wolden-Kirk H, Gysemans C, Verstuyf A, Mathieu C. Extraskeletal effects of vitamin D. Endocrinol Metab Clin North Am 2012;41:571-594. https://doi.org/10.1016/j.ecl.2012.05.004
  3. Garland CF, Garland FC, Gorham ED, et al. The role of vitamin D in cancer prevention. Am J Public Health 2006;96:252-261. https://doi.org/10.2105/AJPH.2004.045260
  4. Holick MF. Vitamin D: its role in cancer prevention and treatment. Prog Biophys Mol Biol 2006;92:49-59. https://doi.org/10.1016/j.pbiomolbio.2006.02.014
  5. Cheung FS, Lovicu FJ, Reichardt JK. Current progress in using vitamin D and its analogs for cancer prevention and treatment. Expert Rev Anticancer Ther 2012;12:811-837. https://doi.org/10.1586/era.12.53
  6. Chung M, Lee J, Terasawa T, Lau J, Trikalinos TA. Vitamin D with or without calcium supplementation for prevention of cancer and fractures: an updated meta-analysis for the U.S. Preventive Services Task Force. Ann Intern Med 2011;155:827-838. https://doi.org/10.7326/0003-4819-155-12-201112200-00005
  7. Krishnan AV, Feldman D. Mechanisms of the anti-cancer and anti-inflammatory actions of vitamin D. Annu Rev Pharmacol Toxicol 2011;51:311-336. https://doi.org/10.1146/annurev-pharmtox-010510-100611
  8. Clinckspoor I, Verlinden L, Mathieu C, Bouillon R, Verstuyf A, Decallonne B. Vitamin D in thyroid tumorigenesis and development. Prog Histochem Cytochem 2013;48:65-98. https://doi.org/10.1016/j.proghi.2013.07.001
  9. Dackiw AP, Ezzat S, Huang P, Liu W, Asa SL. Vitamin D3 administration induces nuclear p27 accumulation, restores differentiation, and reduces tumor burden in a mouse model of metastatic follicular thyroid cancer. Endocrinology 2004;145:5840-5846. https://doi.org/10.1210/en.2004-0785
  10. Liu W, Asa SL, Fantus IG, Walfish PG, Ezzat S. Vitamin D arrests thyroid carcinoma cell growth and induces p27 dephosphorylation and accumulation through PTEN/akt-dependent and -independent pathways. Am J Pathol 2002;160:511-519. https://doi.org/10.1016/S0002-9440(10)64870-5
  11. Balla B, Kosa JP, Tobias B, et al. Marked increase in CYP24A1 gene expression in human papillary thyroid cancer. Thyroid 2011;21:459-460. https://doi.org/10.1089/thy.2010.0420
  12. Roskies M, Dolev Y, Caglar D, et al. Vitamin D deficiency as a potentially modifiable risk factor for thyroid cancer. J Otolaryngol Head Neck Surg 2012;41:160-163.
  13. Penna-Martinez M, Ramos-Lopez E, Stern J, et al. Vitamin D receptor polymorphisms in differentiated thyroid car-cinoma. Thyroid 2009;19:623-628. https://doi.org/10.1089/thy.2008.0388
  14. Stepien T, Krupinski R, Sopinski J, et al. Decreased 1-25 dihydroxyvitamin D3 concentration in peripheral blood serum of patients with thyroid cancer. Arch Med Res 2010;41:190-194. https://doi.org/10.1016/j.arcmed.2010.04.004
  15. Sahin M, Ucan B, Ginis Z, et al. Vitamin D3 levels and insulin resistance in papillary thyroid cancer patients. Med Oncol 2013;30:589. https://doi.org/10.1007/s12032-013-0589-5
  16. Laney N, Meza J, Lyden E, Erickson J, Treude K, Goldner W. The prevalence of vitamin D deficiency is similar between thyroid nodule and thyroid cancer patients. Int J Endocrinol 2010;2010:805716.
  17. Jonklaas J, Danielsen M, Wang H. A pilot study of serum selenium, vitamin D, and thyrotropin concentrations in patients with thyroid cancer. Thyroid 2013;23:1079-1086. https://doi.org/10.1089/thy.2012.0548
  18. Zhang LR, Sawka AM, Adams L, Hatfield N, Hung RJ. Vitamin and mineral supplements and thyroid cancer: a systematic review. Eur J Cancer Prev 2013;22:158-168. https://doi.org/10.1097/CEJ.0b013e32835849b0
  19. Boi F, Minerba L, Lai ML, et al. Both thyroid autoimmunity and increased serum TSH are independent risk factors for malignancy in patients with thyroid nodules. J Endocrinol Invest 2013;36:313-320.
  20. Fiore E, Rago T, Latrofa F, et al. Hashimoto's thyroiditis is associated with papillary thyroid carcinoma: role of TSH and of treatment with L-thyroxine. Endocr Relat Cancer 2011;18:429-437. https://doi.org/10.1530/ERC-11-0028
  21. Wu X, Lun Y, Jiang H, et al. Coexistence of thyroglobulin antibodies and thyroid peroxidase antibodies correlates with elevated thyroid-stimulating hormone level and advanced tumor stage of papillary thyroid cancer. Endocrine 2014;46:554-560. https://doi.org/10.1007/s12020-013-0121-x
  22. Fiore E, Vitti P. Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease. J Clin Endocrinol Metab 2012;97:1134-1145. https://doi.org/10.1210/jc.2011-2735
  23. Paparodis R, Imam S, Todorova-Koteva K, Staii A, Jaume JC. Hashimoto's thyroiditis pathology and risk for thyroid cancer. Thyroid 2014;24:1107-1114. https://doi.org/10.1089/thy.2013.0588
  24. Jankovic B, Le KT, Hershman JM. Clinical review: Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation? J Clin Endocrinol Metab 2013;98:474-482. https://doi.org/10.1210/jc.2012-2978
  25. Choi YM, Kim WG, Kim TY, et al. Low levels of serum vitamin D3 are associated with autoimmune thyroid disease in pre-menopausal women. Thyroid 2014;24:655-661. https://doi.org/10.1089/thy.2013.0460
  26. Choi HS, Oh HJ, Choi H, et al. Vitamin D insufficiency in Korea: a greater threat to younger generation: the Korea National Health and Nutrition Examination Survey (KNHANES) 2008. J Clin Endocrinol Metab 2011;96:643-651. https://doi.org/10.1210/jc.2010-2133
  27. Rosen CJ. Clinical practice: vitamin D insufficiency. N Engl J Med 2011;364:248-254. https://doi.org/10.1056/NEJMcp1009570
  28. Han JM, Kim TY, Jeon MJ, et al. Obesity is a risk factor for thyroid cancer in a large, ultrasonographically screened population. Eur J Endocrinol 2013;168:879-886. https://doi.org/10.1530/EJE-13-0065
  29. Manson JE, Mayne ST, Clinton SK. Vitamin D and prevention of cancer: ready for prime time? N Engl J Med 2011;364:1385-1387. https://doi.org/10.1056/NEJMp1102022
  30. Ferlay J, Shin HR, Bray F, Forman D, Mathers C, Parkin DM. Estimates of worldwide burden of cancer in 2008: GLOBOCAN 2008. Int J Cancer 2010;127:2893-2917. https://doi.org/10.1002/ijc.25516
  31. Kweon SS, Shin MH, Chung IJ, Kim YJ, Choi JS. Thyroid cancer is the most common cancer in women, based on the data from population-based cancer registries, South Korea. Jpn J Clin Oncol 2013;43:1039-1046. https://doi.org/10.1093/jjco/hyt102
  32. Li N, Du XL, Reitzel LR, Xu L, Sturgis EM. Impact of enhanced detection on the increase in thyroid cancer incidence in the United States: review of incidence trends by socioeconomic status within the surveillance, epidemiology, and end results registry, 1980-2008. Thyroid 2013;23:103-110. https://doi.org/10.1089/thy.2012.0392
  33. Kim TY, Kim WG, Kim WB, Shong YK. Current status and future perspectives in differentiated thyroid cancer. Endocrinol Metab (Seoul) 2014;29:217-225. https://doi.org/10.3803/EnM.2014.29.3.217
  34. Holick MF. Vitamin D deficiency. N Engl J Med 2007;357:266-281. https://doi.org/10.1056/NEJMra070553
  35. Choi HS. Vitamin D status in Korea. Endocrinol Metab (Seoul) 2013;28:12-16. https://doi.org/10.3803/EnM.2013.28.1.12
  36. Stolzenberg-Solomon RZ, Jacobs EJ, Arslan AA, et al. Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol 2010;172:81-93. https://doi.org/10.1093/aje/kwq120
  37. Holick MF. Vitamin D status: measurement, interpretation, and clinical application. Ann Epidemiol 2009;19:73-78. https://doi.org/10.1016/j.annepidem.2007.12.001

Cited by

  1. The Role of Vitamin D in Thyroid Diseases vol.18, pp.9, 2017, https://doi.org/10.3390/ijms18091949
  2. Association between vitamin D deficiency and risk of thyroid cancer: a case-control study and a meta-analysis vol.41, pp.10, 2018, https://doi.org/10.1007/s40618-018-0853-9
  3. The Blood Biomarkers of Thyroid Cancer vol.12, pp.None, 2017, https://doi.org/10.2147/cmar.s261170
  4. Immunomodulatory Effects of Vitamin D in Thyroid Diseases vol.12, pp.5, 2017, https://doi.org/10.3390/nu12051444
  5. Nutritional status and follicular-derived thyroid cancer: An update vol.61, pp.1, 2021, https://doi.org/10.1080/10408398.2020.1714542
  6. The Role of Vitamin D as a Prognostic Marker in Papillary Thyroid Cancer vol.13, pp.14, 2017, https://doi.org/10.3390/cancers13143516